Efficacy and safety of filgotinib for refractory pouchitis in patients with ulcerative colitis
Phase 1
- Conditions
- ulcerative colitis, pouchitis
- Registration Number
- JPRN-UMIN000048070
- Lead Sponsor
- Hyogo medical university Department of Gastroenterological Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who dose not agree the treatment with filgochinib.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie JAK1 inhibition by filgotinib in refractory pouchitis of ulcerative colitis patients?
How does filgotinib compare to standard-of-care therapies like antibiotics or immunosuppressants for chronic pouchitis in UC?
Which biomarkers correlate with response to JAK1 inhibitors in ulcerative colitis-associated pouchitis populations?
What adverse events are reported in Phase I trials of JAK1 inhibitors for inflammatory bowel disease, including pouchitis?
Are there combination therapies involving JAK1 inhibitors like filgotinib for refractory pouchitis in ulcerative colitis patients?